A Study of Actonel for the Prevention of Bone Loss

Completed · Phase 3 · Has a placebo group

Conditions studied: Leukemia, Lymphoma

In brief

The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.

Key facts

Study ID
NCT00452439
Run by
M.D. Anderson Cancer Center
People needed
72
Starts
2004-02-01
Expected to finish
2014-08-01
Last updated by the study team
2020-12-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.